SEC Tracker
Get the app
BOLT · XBRL financial data

Bolt Biotherapeutics financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal years (BOLT's year ends in late December)

In thousands of dollarsDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Revenue1,2605,7297,8767,6907,695
Research and development75,65573,12361,54257,46928,533
General and administrative18,39322,92722,53018,45713,795
Total operating expenses94,04896,05084,07280,73843,808
Operating income (loss)(92,788)(90,321)(76,196)(73,048)(36,113)
Income tax expense (benefit)00000
Net income (loss)(98,591)(88,098)(69,197)(63,118)(33,376)
Earnings per share, basic‡ USD per share(59.40)(47.20)(36.60)(33.00)(17.85)
Earnings per share, diluted‡ USD per share(59.40)(47.20)(36.60)(33.00)(17.85)
Weighted average shares, basic‡ thousands of shares1,6611,8681,8911,9091,870
Weighted average shares, diluted‡ thousands of shares1,6601,8681,8911,9091,870
  • ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (June 2025); filings made before it reported them unadjusted.

Balance sheet

CSV

Fiscal years (BOLT's year ends in late December)

In thousands of dollarsDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Cash and cash equivalents27,3839,24410,8107,20511,703
Short-term investments158,836159,64491,37940,11815,802
Prepaid and other current assets2,9413,8583,5192,7072,555
Total current assets189,160172,746105,70850,81430,260
Property and equipment, net6,1586,4534,9573,1391,245
Right-of-use asset24,44522,07219,12021,75619,230
Total assets307,718227,807159,78499,63256,748
Accounts payable3,5743,5942,9871,5071,443
Total current liabilities21,32823,11820,45615,8568,435
Lease liability, non-current21,85420,22017,43722,95820,132
Total liabilities57,59956,30147,04342,43430,243
Accumulated deficit(206,990)(295,088)(364,285)(427,403)(460,779)
Total stockholders' equity250,119171,506112,74157,19826,505
Total liabilities and equity307,718227,807159,78499,63256,748
Common shares outstanding (cover page)‡ thousands of shares1,8731,8911,9061,9171,922
  • ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (June 2025); filings made before it reported them unadjusted.

Cash flows

CSV

Fiscal years (BOLT's year ends in late December)

In thousands of dollarsDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Net income (loss)(98,591)(88,098)(69,197)(63,118)(33,376)
Stock-based compensation8,5009,5769,2237,4072,782
Depreciation and amortization1,1931,6661,8541,7811,291
Net cash from operating activities(57,066)(76,504)(69,525)(61,289)(39,850)
Purchases of property and equipment2,3381,9532064172
Net cash from investing activities(232,201)57,86271,03857,57644,302
Proceeds from issuing common stock1,25250325310819
Net cash from financing activities311,10850325310819
Net change in cash21,841(18,139)1,766(3,605)4,471

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
  • A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Bolt Biotherapeutics12,8605(6,540)*1.9M2.7 quarters 10-QJun 30, 2026
Intensity Therapeutics9,529not reported(2,340)*3.3M4.1 quarters 10-QJun 30, 2026
Zeo ScientifiX2,265not reportednot reported7.8M— 10-KTJun 30, 2026
Genprex15,154not reported(5,139)*819,7092.9 quarters 10-QJun 30, 2026
VivoSim Labs1,67018(3,213)14.9M0.5 quarters 10-QJun 30, 2026
Sunshine Biopharma13,7489,264(918)*3.9M15.0 quarters 10-QJun 30, 2026
Neuphoria Therapeutics19,866year only1,214*5.4M— 10-KJun 30, 2026
CV Sciences2662,98520*225.8M— 10-QJun 30, 2026
Minerva Neurosciences24,652not reported(13,345)*47.7M5.6 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.